{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Neoadjuvant Therapy in Primary Metastatic Rectal Cancer"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Conducted in seven centers in The Netherlands, the trial included 50 patients"
      },
      "Participants": {
        "score": 2,
        "evidence": "50 patients with histologically confirmed rectal adenocarcinoma and potentially resectable or ablatable liver or lung metastases"
      },
      "Intervention": {
        "score": 2,
        "evidence": "short-course radiotherapy followed by systemic therapy with capecitabine, oxaliplatin, and bevacizumab, and subsequent radical surgical treatment"
      },
      "Objective": {
        "score": 1,
        "evidence": "This phase II trial evaluated the efficacy of short-course radiotherapy followed by systemic therapy"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the percentage of patients receiving radical treatment of all tumor sites, assessed over a median follow-up of 8.1 years"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and allocation concealment methods were not applicable as this was an open-label study"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not implemented"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "the trial included 50 patients"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "All 50 patients were analyzed"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "16 patients (32%) were alive, and 14 (28%) were disease-free. Median overall survival was 3.8 years"
      },
      "Harms": {
        "score": 0,
        "evidence": "Adverse events were not detailed in the manuscript"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NTR2029"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified"
      }
    },
    "total_score": 14,
    "max_score": 25
  },
  "model": "gpt-4o"
}